Oral single-active pantothenic acid and fasting triglycerides in adults with hypertriglyceridemia

Complete submitted research report

# Oral single-active pantothenic acid and fasting triglycerides in adults with hypertriglyceridemia

**TASK-1035 / R01-075 · Completed current-value report · Full English version** Search and verification date: **2026-09-17**. Supplied snapshot: **2026-09-17T12:07:38+09:00**. The snapshot was not assumed to be identical to the current live website. Efficacy grade **?** · score **null, not zero** · safety **Caution** · document quality **A, self-assessed**. Result: `completed_with_uncertainty`; content readiness: `ready_with_uncertainty`. New publication identifiers remain unassigned.

## 1. The 30-second answer

Within the disclosed search, **no directly eligible result was verified that establishes how much oral single-active pantothenic acid changes fasting triglycerides (TG) versus a comparator in adults with hypertriglyceridemia.** Human B5 trials exist, but the closest registered trial has no TG result in its accessible posted results, while several favorable lipid findings concern different interventions such as pantethine or CoA. This finding therefore does **not** establish zero effect, equivalence to placebo, absence of all human research, or confirmed safety. [S01–S06]

The current answer is that the magnitude of lowering is unverified. Within-group pantethine reductions, changes during shared dietary counseling, circulating or microbial pantothenic-acid associations, and animal mechanisms were not relabeled as the isolated pantothenic-acid between-group fasting-TG effect. Research doses below are factual records, not personal dosing advice, instructions to stop lipid medication, or a replacement for standard care.

## 2. The question boundary versus actual study facts

| Item | Present question | Separation from the actual evidence | |---|---|---| | Intervention | Oral single-active pantothenic acid | Actual salt, active amount, sole-active composition and total intake require study-specific verification. Pantethine, CoA, topical/injected panthenol or dexpanthenol, and mixtures are not automatically equivalent interventions. | | Population | Adults with hypertriglyceridemia | Diabetes or metabolic-syndrome labels alone do not establish hypertriglyceridemia in every participant. Actual diagnostic criteria, baseline TG and deficiency status remain separate fields. | | Endpoint | Between-group fasting-TG difference at a defined time | Nonfasting/postprandial TG, LDL-C, HDL-C, total cholesterol, apoB, liver fat, HbA1c, pancreatitis and cardiovascular events are separate outcomes. | | Comparator | Actual placebo, usual care or an appropriate active comparator | Candidate comparators in the question were not filled in as actual study conduct. Shared medication, diet and lifestyle management were distinguished from the incremental component effect. | | Actual eligible dose, duration and control | Unverified | No directly eligible result was identified, so the adjacent trial's 250 mg/8 weeks or pantethine doses were not substituted. |

The supplied taxonomy supports `kind=S` for a single-nutrient/supplement question and `category=heart` for a lipid question. `R01` and `NUT` are research-allocation/domain modules, not new top-level site categories. New ID, slug, URL, first-publication time and semantic codes remain `null`; none was reserved arbitrarily. The supplied codebook distinction between pantothenic acid and pantethine was retained. [Inputs: selected task/module, taxonomy and codebook]

## 3. Input identity, duplicate review and reuse

The exact input ZIP is **2,011,529 bytes, 58 files and 10,845,146 uncompressed bytes**, with SHA-256 **f8bf192d4f7d61844175f1f761abef3a42dd266fa2030fd202196fc1f716a67e**. Identities declared for non-self members in its manifest were checked, while the manifest itself was checked through the external inventory. Every member was preserved byte-for-byte, with a mapping from original Korean paths to new ASCII storage paths. The separately attached prompt exactly matches the full prompt inside the ZIP. [input_provenance.json; input_read_audit.json]

The full **3,150-record index**, **nine native candidates**, **5,655 codebook entries**, common/R01/NUT instructions, original rubric/calculator, output structure and prior completion records were read. The nine automatic candidates differ in endpoint or claim type as shown below. Additional index matches from pantothenic-acid/pantothenate, pantethine, panthenol/dexpanthenol and vitamin-B5 terms were also distinguished. Candidate presence or absence alone was not used to establish novelty.

| Existing ID | Completed boundary | Reuse here | |---|---|---| | 028 | Composite skin/hair claim | Historical claim boundary and source map | | 3099 | Inflammatory acne lesion counts | Single-product and skin-claim boundary | | 3100 | Elevated LDL-C concentration | Pantethine/acid distinction, lipid sources and mixture/nonhuman exclusion map | | 3101 | Nonspecific persistent fatigue, FSS | Endpoint separation | | 3102 | Diarrhea risk after oral exposure | Existing short-term healthy-adult safety extraction | | 3147, 3148, 3149 | Complete epithelialization, stratum corneum hydration, TEWL | Intervention, safety and completed-claim boundaries | | 3150 | HbA1c in adults with type 2 diabetes | Item 74's original extraction, search/safety map and IRCT source |

Additional index ID **366** concerns pantethine, and **2466** concerns a topical eyelid-cleansing product containing panthenol and other ingredients. Neither is the same claim. These were checked at index level and through citations already present in supplied candidates; no new full native files for those two IDs were obtained or claimed. No exact completed duplicate was identified within the supplied scope, so `operation=new`. Prior B6, skin, HbA1c and items 70–74 were not reinvestigated, rescored or retranslated. [evidence_boundary.json; reuse_map.json]

The original manifests/resumes/sources/verification reports/full bilingual reports for 70–74→3146–3150 and their **six-route deployment receipts** were cross-checked within the local input. Historical unassigned IDs were preserved as historical values, not confused with current completion records. The legacy `previous_conversation_completed` key means the previous five completed tasks; only **item 74** had already been fully completed in this chat. The supplied **69 published, 5 exact duplicates, 26 pending, completed range 74** remain the pre-deployment baseline. This research delivery was not counted as live deployment, and no live site was accessed for rechecking. [prior_completion_validation.json]

## 4. Actual search coverage and access limitations

On 2026-09-17, **28 search expressions were logged** using Korean/English ingredient names, salts, TG, hypertriglyceridemia, randomization/placebo, fasting, registration and correction/retraction terms. This is a count of logged expressions, not papers or total database hits. Examples include `"pantothenic acid" "triglycerides" randomized placebo`, `"calcium pantothenate" "triglycerides" human`, `"pantothenate" "hyperlipidemia" trial`, and the Korean pantothenic-acid/hypertriglyceridemia/randomized-trial expression. Queries with and without pantethine exclusions and exact prior lipid-study identifiers were used. [search_log.json]

Sources actually used were the web index, readable primary PubMed abstracts, primary IRCT registry/posted-result HTML, the official NIH document and exact prior extractions in the current input. Subscription Embase, native CENTRAL/WHO ICTRP/Korean database censuses, author/IPD requests and all-language/all-reference-chain coverage were not performed. A Europe PMC API request was executed but failed DNS without returning results. Some native PubMed/ClinicalTrials.gov search openings also failed to provide a complete readable export; they were not counted as successful native database searches.

Current Evans full-text access returned CAPTCHA/empty responses; Chen abstract/DOI routes returned empty responses/errors; Luo's full-text link failed. The IRCT PDF was also unavailable in this task, although its HTML registration and result tables were readable. No new PDF screenshot verification is claimed. Historical PDF/table-image inspection in the input is explicitly **reused provenance**, not a screenshot taken for this task. A 2026 search-title lead mentioning liposomal vitamin B5 could not be resolved to its exact text and was neither verified as a new clinical trial nor definitively excluded as one. Irrelevant homepages and keyword-only hits were not promoted to evidence.

Correction/retraction queries were attempted but some results were unrelated. No complete publisher Crossmark or all-correction-record clearance is claimed. The conclusion is limited to the current verified scope, including these access and search limitations. [sources.json; search_log.json]

## 5. Expert evidence table

No directly eligible TG result was verified. These **10 study families** are a boundary map of inspected/reused related material, not “10 eligible clinical trials.” Reviews and their source trials, overlapping cohorts and potentially related preprints were not counted as independent replications.

| Study/access | Actual intervention, control and denominator | TG-related verification | Classification and reason for exclusion from direct efficacy | |---|---|---|---| | **S01 IRCT20230702058641N2**; primary registry/result HTML and item-74 extraction | B5 tablet label 250 mg/day, placebo, background metformin/insulin in both groups; planned 8 weeks. Target 48; posted table 19+19 and results abstract 38 | Registered primary DASS-21; no TG in accessible posted results. Hypertriglyceridemia diagnosis, TG assay and sole-active amount unverified | Establishes related human research. Target population/endpoint eligibility unverified; not a null trial | | **S02 Gaddi 1984**; primary abstract | Pantethine 300 mg three times daily versus placebo, crossover-type design; 29 participants, 8-week treatment descriptions | About 30% reduction with pantethine first; after placebo, 17.8% in IIB and 13.0% in IV, relative to baseline | Wrong molecule. Actual fasting conditions, raw TG concentrations and adjusted between-treatment effect/CI unverified | | **S03 Evans 2014**; inherited primary extraction, current full-text failure | Pantethine 600→900 mg/day, placebo plus TLC diet, 16 weeks; 32 randomized/24 completed | No newly verified TG values, TG analysis denominator or original TG table | Wrong molecule. Prior LDL verdict/numbers not reassessed | | **S04 Rumberger 2011**; primary abstract | Pantethine versus placebo, 120 participants/60 per group; 4-week TLC run-in then 16 weeks, 600→900 mg/day | Abstract emphasizes TC/LDL-C/apoB, not a fasting-TG contrast | Wrong molecule. Shared investigators with Evans not automatically independent replication | | **S05 Chen 2015**; official NIH map, primary abstract inaccessible | NIH summary: 216 hypertriglyceridemic adults, CoA **400 U/day** versus pantethine 600 mg/day, shared dietary counseling, 8 weeks | Primary fasting conditions, assay and between-group effect/CI unverified | Neither arm is isolated pantothenic acid. U not converted to mg | | **S06 Luo 2026**; primary abstract/metadata | Human metabolic-syndrome association and microbial/mouse/organoid models | Human isolated oral pantothenic-acid fasting-TG treatment effect unverified | Human data exist, but association/mechanism is not an isolated-product clinical effect | | **S07 Zhao 2024**; inherited primary abstract extraction | Mice and primary adipocytes, potentially related preprint | Fat-deposition/signaling mechanisms | Nonhuman; preprint not counted as separate replication | | **S08 NCT03444155**; inherited protocol extraction | Natural versus synthetic B-complex products | Actual TG results/denominators not newly verified | Multicomponent; a plan is not observed conduct/results | | **S09 Rao 2021**; existing safety extraction | Healthy adults 18–55, open-label uncontrolled, 40 completers: 32 single-dose/8 repeated-dose | Pharmacokinetic/diarrhea data, not a TG efficacy trial | Safety context only, not efficacy or long-term safety in hypertriglyceridemia | | **S10 Shoura 2025**; item-74 original extraction | Plasma pantothenic-acid biomarker in diabetes/cardiovascular groups | Association rather than isolated oral exposure effect | Exposure/design boundary reused without reanalysis of the completed HbA1c work |

`study_extractions.json` records **52 fields per study**, with values and explicit uncertainty states. `not_reported` means not extracted from the **named accessed material**, not proven absent from an inaccessible full paper. Protocol descriptions are separately marked `actual_observed_fact=false` where applicable.

### 5.1 The closest B5 trial: why actual human data do not become TG efficacy data

IRCT registered the study while recruiting on 2024-02-01; results were posted on 2024-09-21. Its registered primary outcomes are depression, anxiety and stress measured with DASS-21, with cortisol and oxidative-stress measures as secondary outcomes. Posted fasting blood sugar is not TG. Whether TG was collected, actual fasting hours, serum/plasma TG assay and units, baseline/end-of-study arm values and a between-group estimate were not verified. Unreported TG was not invented as a positive or negative post hoc finding. [S01]

The difference between the target of 48 and 38 publicly described participants was not labeled “10 dropouts.” Actual randomized/withdrawal flow, variable-specific analysis denominators, ITT, missing-data methods, adherence and treatment changes are unverified. The baseline medication table identifies metformin/insulin use but does not establish actual control of lipid medication, diet, alcohol, kidney function or total B5 intake. B5 nutritional-status values/scales conflict between baseline and outcome tables, with units and deficiency definitions unverified; the trial was not classified as deficiency correction. [S01; reused input3150]

A 250 mg chewable B5 tablet and placebo matching appearance, taste and color are registration descriptions, not verification of complete ingredients, salt/active amount, impurities/batch or successful masking. Funding is recorded as 100% public support from Shahre-kord University of Medical Sciences. Shehab is a named manufacturer, not necessarily a product donor. The empty adverse-event table was not converted to zero events. [S01]

### 5.2 Favorable pantethine lipid signals are acknowledged without changing the molecule

Gaddi's abstract describes plasma-TG lowering with pantethine. The 29 participants comprise 11 type-IIB, 15 type-IV and 3 isolated low-HDL cases, rather than one uniform hypertriglyceridemic group. Sequence-dependent reductions were preserved. About 30%, 17.8% and 13.0% are **source-reported relative reductions**, not pantothenic-acid mg/dL changes or placebo-adjusted between-group percentage-point effects. Baseline TG, sequence denominators/variance, washout/carryover and paired analyses were not available in the accessed abstract, so no independent-parallel-arm CI was fabricated. The abstract's description of no overt side effects is not a detailed event table or safety confirmation. Named funding and product provision are unverified. [S02]

The Evans 32-participant study was reused through the exact current-input extraction. Rumberger's 120-participant abstract was inspected for this question's intervention/endpoint boundary. Its actual comparison is pantethine versus placebo with **TLC diet in both arms**; completer/ITT details and TG methodology are unverified in the accessed abstract. Evans's prior extraction names Daiichi Fine Chemical support, whereas named Rumberger support was not verified from this abstract. Shared authorship and overlapping participants are distinct issues; participant overlap was not established. Neither report was counted in the replication axis for isolated pantothenic acid. [S03–S04]

Chen is an **active-comparator CoA-versus-pantethine trial** mapped through the official NIH summary. Primary-abstract access failure is disclosed, and precise secondary figures/ranges were not promoted to original-table-verified results. Baseline-to-follow-up changes during common dietary counseling were not used to infer an independent component effect. Pantethine is not pantothenic acid, and CoA is not the same intervention as oral single-active pantothenic acid. [S05; S11]

### 5.3 The 2026 mechanistic study and existing observational/mixture evidence

The primary index lists Luo as published online on 2026-07-01 and in the 2026-09-09 issue. It combines human metabolic-syndrome associations with microbial pantothenic-acid supply and model/organoid work involving bacterial panC and host PANK2/3. The paper is therefore not described as having no human data. However, its accessed abstract does not establish a placebo-controlled TG effect from administering isolated oral pantothenic acid to hypertriglyceridemic adults. Full text, supplements, human sample size, administered dose, actual TG assay and funding remain unverified. A declaration of no competing interests was separated from verified independent funding. [S06]

Only the relevant existing boundaries were reused for Zhao animal/cell mechanisms, the NCT03444155 B-complex protocol and the plasma-biomarker study. Food, dietary or circulating associations, products containing additional ingredients and nonoral interventions cannot identify this isolated effect. These materials were not classified as direct “disproof trials” either. [S07–S10]

## 6. Laboratory, numerical and design verification

**Actual TG laboratory conditions.** No eligible comparison supplied verified fasting hours, permitted intake, sampling times, serum/plasma matrix, instrument/assay, calibration/interference or glycerol-blanking details. Gaddi specifies plasma TG, but fasting conditions and TG concentration units were not verified from the abstract. The IRCT fasting-glucose label and fasted administration in Rao's safety study were not transferred to fasting-TG sampling. Generic laboratory practice was not filled in as study fact. [S01–S02; S09]

**Units and distributions.** mg/dL and mmol/L describe TG concentrations; percentages describe relative change. No numerical unit conversion was performed because no eligible original TG concentration was verified. A relative decline without a verified baseline was not converted to an absolute reduction, nor were LDL conversion conventions or CoA activity units substituted for pantothenate mass. Arithmetic means, geometric means, medians, original/log-transformed scales and SD/SE/CI were not interchanged when unverified.

**Within-group versus between-group.** Relative change from baseline is `(end−baseline)/baseline×100`; a same-time between-group change contrast is the difference between the two arm changes. The existence of a formula does not establish the required data. An unadjusted endpoint difference was not substituted for a comparison requiring adjustment, and crossover observations were not treated as independent arms to manufacture a CI. Unverified registered primary/secondary status, post hoc analyses, multiplicity and co-primary failure remain unverified. Statistical significance in related lipid findings was not relabeled as clinically important pantothenic-acid efficacy or clinical-event prevention.

Actual arithmetic checks were limited to **pantethine 300×3=900 mg/day**, **11+15+3=29 participants**, and **IRCT 19+19=38 participants**. Original labels versus recalculations, units, direction and purpose are separated in `numerical_audit.json`. Recruitment-target differences were not converted to withdrawals, and these checks are not represented as calculations of a pantothenic-acid TG effect.

Eligible mean difference, SD/SE/CI, standardized effect, MCID, ARR and NNT remain **unverified/null**. P values for another ingredient were not used to back-calculate this effect. A TG surrogate cannot supply pancreatitis or cardiovascular-event ARR/NNT without eligible event data. Unverified effect, zero effect, failure to reach clinical importance and equivalence are distinct conclusions. [numerical_audit.json; original rubric]

## 7. Safety is separate from efficacy: Caution

The existing Rao short-term healthy-adult extraction was reused without rescoring the diarrhea question. The product is described as oral D-calcium pantothenate tablets. Paper-labeled single doses of 500/1,000/2,000/5,000 mg were separated from 2,000 mg/day repeated for 14 days. Because the acid-versus-salt labeling basis was not fully resolved, actual pantothenic-acid active quantity was not converted. Total dietary and other supplemental intake remains unverified. [S09; input3102]

The prior observation of diarrhea in 1/8 after a fasted 5,000 mg single dose and 0/8 during subsequent fed exposure in the same eight people was preserved. These are not 16 independent participants. The open-label uncontrolled design does not establish a placebo-adjusted risk difference, NNH or population incidence. The total 40 completers—32 single-dose and 8 repeated-dose—were not conflated with condition-specific denominators. Funding and employment/consultancy/shareholdings were retained from the prior extraction; free product provision was not inferred. [S09]

NIH describes diarrhea/GI discomfort with high intake, no established UL, and no known clinically relevant medication interactions. These statements do **not** confirm an unlimited safe dose, compatibility with every lipid medication, or long-term safety. Safety in hypertriglyceridemia, diabetes, impaired kidney/liver function, pregnancy/lactation, children, prolonged high-dose use and actual combined intake is not established by these data. Unreported adverse events were not interpreted as proof of safety. [S11]

“Caution” is an editorial label for observed signals and uncertain applicability, not an individual risk prediction or efficacy grade. Research doses are not dosing recommendations, and this report does not instruct stopping lipid medication or replacing standard treatment.

## 8. Current judgment completed with the supplied rubric and original calculator

The **unchanged bytes** of the supplied `참고자료/등급도출.py` were actually executed. `derive_grade`, `validate_axes` and `check_verdict` were applied to this task only. Execution results and original-file SHA are in `grading_result.json`. No completed prior verdict was recalculated.

| Item | Value and interpretation | |---|---| | Claim type | `B`: clinical efficacy question | | Endpoint | `S`: fasting-TG surrogate, not a clinical event | | Legacy gate | `no_human_study=true` is restricted to **no verified eligible direct result for this intervention/population/outcome/comparison within the disclosed search** | | Related human research | `human_study_exists=true`; `all_human_studies_absent=false` | | Other efficacy axes | Replication, independence, effect, bias and precision are unscored `null`; excluded studies are not assigned arbitrary axes | | Proposed/final grade | `? / ?`, without override | | Score | `null`, not zero or an invented substitute for an A–F anchor | | Document quality | `A`: self-assessment of completed source tracing, boundaries, uncertainty, bilingual content and requested structure |

The gate was not automatically triggered by access failure alone. It reflects the **question-limited current value** after examining the actual B5 registry/results without TG, molecule mismatches in inspected/reused pantethine/CoA lipid studies and design mismatches in observational, mixture and nonhuman materials. It must not be published as “no human research of any kind exists.” The same restriction is explicit in both languages' assessment/editorial scope and structured fields.

Chamgap grades/scores are supplied-rule indices, not treatment-success probabilities, formal GRADE or journal certification. Document quality A does not establish efficacy or guarantee absence of errors.

## 9. Remaining uncertainty and revision conditions

The directly eligible fasting-TG effect, CI and MCID remain unverified, as do actual sole-active composition, salt/active amount, total intake, diagnosis/baseline TG, nutrition/deficiency, diet/alcohol, kidney function, lipid co-medication, lifestyle/treatment changes, adherence, TG laboratory/distribution details, analysis denominators/missingness and adequate safety denominators or long-term/special-population safety. Unreported, inaccessible and inapplicable states are separated by study, not converted to either a hold or zero effect.

A new directly eligible trial; missing primary text, TG results, composition, analysis plan or participant flow; a correction/retraction or identifier error; or a change to molecule/route/population/endpoint boundaries would trigger revision. Obtaining a pantethine paper does not make it the same molecule as pantothenic acid. After publication, any revision would retain the assigned ID/URL and record old/new values, reasons, sources and dates. **These are revision conditions, not clinical searching, rescoring or translation-review TODOs handed to Codex.**

## 10. Self-review, content readiness and technical restoration are distinct

The same author self-reviewed inputs, source access levels, numbers, safety, molecule/outcome boundaries, classification, original-calculator output, bilingual meaning and fields. Actual work/nonperformance, arithmetic, prepublication audit and automated supporting checks are recorded in `verification_report.md` and `clinical_verification_result.json`. `independent_review=false`. **This is not independent external peer review, journal certification or an error-free guarantee.**

Each language's `body_markdown` is the exact full text of its respective Korean or English report. The short initial `what_research_original` is also preserved in a separate file. Initial public `corrections=[]` is separate from the prepublication audit. New ID/slug/URL/first-publication time/semantic codes remain unassigned `null`, with `needs_id_assignment=true`. `ready_with_uncertainty` is content readiness, not completed deployment.

Disk rereading of the frozen transport, exact-byte restoration, separate recompression and all-member checks are **technical verification**. Actual execution values belong in the accompanying external integrity and restoration receipt; future hashes or unperformed restoration claims are not fabricated inside the frozen manuscript. The technical tool does not run clinical tools. No server administration/deployment, subagent, new conversation or automatic item-76 start is performed for this task.

## Sources and access locations

- **S01** [IRCT20230702058641N2 registry and posted results](https://en.irct.ir/trial/74085). Primary registration/result HTML; exact current-input TASK-1034 S01 extraction also reused. Current PDF unavailable. - **S02** [Gaddi 1984, PMID 6365107](https://pubmed.ncbi.nlm.nih.gov/6365107/). DOI `10.1016/0021-9150(84)90009-1`; bibliography/primary abstract, plasma TG and sequence-specific relative changes. - **S03** [Evans 2014, PMC3942300](https://pmc.ncbi.nlm.nih.gov/articles/PMC3942300/). DOI `10.2147/VHRM.S57116`, PMID `24600231`; exact input3100 primary extraction reused; current full-text access failed. - **S04** [Rumberger 2011, PMID 21925346](https://pubmed.ncbi.nlm.nih.gov/21925346/). DOI `10.1016/j.nutres.2011.08.001`; primary-abstract intervention, diet, denominator and endpoint boundary. - **S05** [Chen 2015, PMID 26350816](https://pubmed.ncbi.nlm.nih.gov/26350816/). Primary page empty. Material actually used: **official secondary mapping** in S11 Hyperlipidemia/reference21. No primary-verified DOI supplied. - **S06** [Luo 2026, PMID 42385714](https://pubmed.ncbi.nlm.nih.gov/42385714/). DOI `10.1016/j.chom.2026.06.005`; primary abstract/metadata/conflict statement, full text unavailable. - **S07** [Zhao 2024, PMID 38949913](https://pubmed.ncbi.nlm.nih.gov/38949913/). DOI `10.1089/jmf.2023.k.0292`; input3100 S103/S104 prior extraction and preprint lead reused. - **S08** [NCT03444155](https://clinicaltrials.gov/study/NCT03444155). Input3100 S105/S106 B-complex protocol extraction reused; v1.2, 2017-04-13, printed pages5–6. No new PDF inspection in this task. - **S09** [Rao 2021 healthy-adult calcium-pantothenate pharmacokinetics](https://www.gavinpublishers.com/article/view/the-pharmacokinetics-of-orally-administered-calcium-pantothenate-in-healthy-adults). Inherited DOI `10.29011/JVM-106.100006`; input3102 and TASK-1034 S07 primary extractions reused, not a new safety investigation. - **S10** [Shoura 2025 plasma biomarker](https://www.nature.com/articles/s41598-025-19271-5). DOI `10.1038/s41598-025-19271-5`; input TASK-1034 S02 exposure boundary reused. Previously unverified table images remain unverified. - **S11** [NIH ODS Pantothenic Acid—Health Professional](https://ods.od.nih.gov/factsheets/PantothenicAcid-HealthProfessional/). Updated2026-05-01; Hyperlipidemia, Health Risks, Interactions and references. Official background/safety/source map, not a direct efficacy trial.

Exact supplied original/instruction bytes and paths are preserved in `input_provenance.json` and `input_originals/`; new source identifiers, access levels and limitations are in `sources.json`. No publisher-binary hash was fabricated without obtaining that binary.